What does a cruise-and-blast protocol involve when using Testosterone Undecanoate?

A cruise-and-blast protocol alternates between a blast phase — where testosterone dosage is intentionally elevated to drive muscle and strength gains — and a cruise phase, where it is reduced to a near-physiological level to allow partial hormonal recovery. Testosterone Undecanoate's slow-release profile reduces injection frequency in both phases, making phase transitions easier to manage without abrupt hormonal swings.

How long should the cruise phase last before returning to a blast?

Most practitioners run the cruise phase for a minimum of eight to twelve weeks to allow meaningful recovery of endogenous hormonal markers before the next blast. The exact duration should be guided by serum testosterone trough readings and LH/FSH monitoring, not a fixed calendar schedule. Testosterone Undecanoate's long half-life means trough levels decline gradually, making the cruise phase transition smoother compared to shorter esters.

At what signal should you switch from blast to cruise with a long-acting undecanoate?

The switch from blast to cruise is typically triggered by reaching a pre-planned accumulation target — often confirmed by a serum testosterone measurement showing stable supraphysiological levels — combined with a structured assessment of recovery markers such as haematocrit, blood pressure, and lipid panels. With Testosterone Undecanoate, practitioners reduce the injected volume rather than changing compounds, maintaining protocol continuity.

How is the 250mg/ml concentration useful when adjusting volume between cruise and blast phases?

At 250mg/ml, each 0.5ml increment represents a meaningful and measurable dose adjustment, giving the practitioner fine-grained control when stepping down from blast-phase volumes to cruise-phase volumes using the same vial. This avoids the need to switch between product concentrations mid-cycle, reducing calculation errors. HPLC verification of the stated concentration means dose calculations are built on confirmed API content rather than label assumption.

What are the storage requirements for a Nassa Labs Testosterone Undecanoate 10ml vial once opened?

Once a multi-dose vial is broached, it should be stored upright at controlled room temperature (15–25°C), away from direct light and heat, and used within the period specified on the product label — typically 28 days after first puncture. Refrigeration is not required but the vial must never be frozen, as this can alter the oil carrier. Each draw should be taken with a fresh, sterile needle to prevent contamination across the long multi-dose cycle. (2) angle_used

Brand Quality

Nassa Labs

Testosterone Undecanoate 250mg/ml 10ml Vial by Nassa Labs

Name: Testosterone Undecanoate 250mg/ml 10ml Vial by Nassa Labs
Brand: Nassa Labs
SKU: INJ-TUND-NAS-250-004
Price: 50.00 EUR
Availability: InStock

Nassa Labs Testosterone Undecanoate 250mg/ml is a long-acting oil-based injectable androgen delivering stable plasma testosterone across extended multi-phase programmes, with slow enzymatic ester cleavage that supports infrequent administration throughout both elevated and maintenance dosing intervals. Each 10ml vial provides sufficient volume to carry an athlete through complete phase transitions, eliminating mid-protocol resupply as a logistical variable for those who structure anabolic exposure with precision. Batch release is conditional on HPLC content verification and LAL endotoxin clearance — both outcomes are documented in a retrievable per-lot certificate before any vial leaves the Nassa Labs facility.

€50.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Supports phase-separated cycling: elevated blast exposure followed by a controlled cruise interval from a single 10ml supply.
Reduces injection frequency in both phases compared to short-ester testosterone protocols.
HPLC-verified API content at 250mg/ml ensures accurate volume-to-dose calculations across every phase.
LAL endotoxin clearance on each batch reduces the risk of injection-site inflammatory responses during long-cycle use.
Independent batch-release protocol at Nassa Labs prevents distribution of lots that have not cleared analytical review.
Multi-dose 10ml vial format supports seamless phase transitions without mid-protocol resupply.
Consistent oil-based formulation allows predictable absorption kinetics when planning blast-to-cruise transitions.

Phase	Typical Dose	Interval	Note
Blast (accumulation)	500–1000mg per injection	Every 10–14 days	Confirm stable supraphysiological trough before sustaining; adjust volume using the 250mg/ml concentration
Cruise (maintenance)	125–250mg per injection	Every 14 days	Reduce injected volume from the same vial; monitor serum testosterone and haematocrit
Phase transition	Taper blast dose by ~50% over one injection interval	As needed	Use a serum trough reading to confirm the shift to cruise is appropriate before fixing the new interval
Pre-PCT washout	No further administration	12–16 weeks post-last injection	Long half-life requires an extended washout; confirm testosterone trough before initiating PCT agents

Key takeaways

Structure your blast phase with elevated doses, then cruise at reduced volume from the same vial.
Rely on serum trough measurements — not guesswork — to time each phase transition.
Verify batch potency: every Nassa Labs lot carries an HPLC content certificate.
Store the opened 10ml vial at 15–25°C and replace the needle before each draw.
Use the 250mg/ml concentration to adjust cruise versus blast volumes without switching products.

Testosterone Undecanoate as a Cruise-and-Blast Foundation

Nassa Labs Testosterone Undecanoate 250mg/ml is an injectable androgen ester engineered around a slow-release profile that makes it uniquely suited to protocols where the practitioner intentionally alternates between a high-stimulus blast phase and a lower-dose cruise phase. Unlike shorter testosterone esters that require frequent injections to maintain stable plasma levels, Testosterone Undecanoate's extended absorption window reduces injection frequency during both phases, lowering the administrative burden across a long-term cycling plan. The 10ml vial format supports multi-phase programming without the logistical disruption of mid-cycle restocking.

How Cruise-and-Blast Periodisation Works with Long-Acting Esters

The cruise-and-blast model divides anabolic exposure into two distinct periods: a blast phase, in which testosterone dosage is elevated to stimulate hypertrophy and strength adaptation, and a cruise phase, in which dosage is reduced to a physiological or near-physiological range to allow partial recovery of endogenous hormonal signalling. Testosterone Undecanoate supports this structure because its slow enzymatic cleavage of the undecanoate sidechain — confirmed by published pharmacokinetic studies measuring serum free testosterone via immunoassay — allows plasma concentrations to remain detectable across longer dosing intervals compared to propionate or enanthate esters. Practitioners typically use serum trough measurements taken immediately before a scheduled dose to confirm whether a phase transition is appropriate, providing objective data rather than calendar-based guesswork.

Phase-Specific Dosing Considerations

During the blast phase, many users administer Testosterone Undecanoate at intervals of approximately every 10 to 14 days, with dose volume calibrated to their target weekly testosterone exposure. During the cruise phase, the same 250mg/ml concentration allows the practitioner to reduce the administered volume rather than switching compounds, maintaining product consistency throughout the entire protocol. Nassa Labs supplies the compound at a concentration where each millimetre of solution represents a predictable steroid load, and HPLC quantification against a certified reference standard confirms actual API content matches the declared label claim — a critical assurance when phase-dosing accuracy depends on knowing exactly what each injection contains.

Quality Infrastructure Supporting Long-Cycle Use

Long-duration protocols demand confidence in batch-to-batch consistency; a vial drawn in week two of a blast must match the potency of the vial drawn in week sixteen of the same cycle. Nassa Labs addresses this through an independent analytical release protocol: finished-batch HPLC content assay and LAL endotoxin testing must both pass before a lot code is assigned, and those records are linked to the vial's individual batch number. This traceability ensures that every phase of a cruise-and-blast programme is supported by verified, documented product quality.

Usage

Plan your phase structure before the first injection.: Decide the target duration and dose range for your blast phase and your intended cruise dose, so that every vial draw is deliberate and traceable to a phase objective.
Inspect the vial before use.: Confirm the lot number, check for particulate matter or colour change, and verify the stopper has not been previously compromised. Nassa Labs vials are sealed with crimped aluminium — any broken seal is a discard criterion.
Draw with a wide-gauge needle, inject with a finer one.: Use an 18-gauge draw needle to pull the oil-based solution efficiently, then switch to a 23–25 gauge injection needle of appropriate length for your chosen intramuscular site (gluteal, vastus lateralis, or deltoidal).
Aspirate and confirm placement.: Before depressing the plunger, aspirate briefly to confirm the needle tip is not in a blood vessel — a critical safety step during both blast and cruise phase injections.
Inject slowly and rotate sites.: Depress the plunger at a controlled rate (approximately 30 seconds per ml) and rotate injection sites across the cycle to prevent cumulative tissue irritation.
Log each injection date, volume, and phase.: Maintaining a written or digital log of every draw — including the lot number — allows accurate serum-trough timing and provides a clear record if dose adjustments are needed when transitioning between blast and cruise.

Warnings

Contraindications:

Testosterone Undecanoate is contraindicated in individuals with androgen-sensitive carcinoma (prostate or breast), untreated polycythaemia, severe hepatic impairment, or hypersensitivity to any component of the formulation. Individuals with a history of thromboembolic events should not use this compound without specialist medical supervision.

Side Effects:

Supraphysiological androgen exposure during the blast phase may cause erythrocytosis (elevated haematocrit), acne, androgenic alopecia, elevated blood pressure, and suppression of endogenous gonadotrophin secretion. Oedema secondary to sodium retention can emerge, particularly at higher blast-phase volumes. Injection-site reactions are generally mild with properly administered oil-based formulations.

Monitoring:

Haematocrit should be measured before initiating the blast phase and at eight-week intervals throughout. Lipid panels (total cholesterol, HDL, LDL), liver enzyme levels (ALT, AST), blood pressure readings, and PSA in males over 40 should be assessed at each phase-transition point. Serum testosterone trough measurements taken immediately before the next scheduled injection are the recommended tool for confirming dosing interval appropriateness.

PCT:

Post-cycle therapy is required after any blast-and-cruise programme that concludes with full cessation. Due to Testosterone Undecanoate's extended release profile, an adequate washout period — typically 12 to 16 weeks from the final injection — is required before beginning PCT agents such as clomiphene citrate or tamoxifen. Initiation of PCT should be guided by a confirmed serum testosterone trough below a pre-agreed threshold, not by a fixed calendar date.

Frequently asked questions

What does a cruise-and-blast protocol involve when using Testosterone Undecanoate?: A cruise-and-blast protocol alternates between a blast phase — where testosterone dosage is intentionally elevated to drive muscle and strength gains — and a cruise phase, where it is reduced to a near-physiological level to allow partial hormonal recovery. Testosterone Undecanoate's slow-release profile reduces injection frequency in both phases, making phase transitions easier to manage without abrupt hormonal swings.
How long should the cruise phase last before returning to a blast?: Most practitioners run the cruise phase for a minimum of eight to twelve weeks to allow meaningful recovery of endogenous hormonal markers before the next blast. The exact duration should be guided by serum testosterone trough readings and LH/FSH monitoring, not a fixed calendar schedule. Testosterone Undecanoate's long half-life means trough levels decline gradually, making the cruise phase transition smoother compared to shorter esters.
At what signal should you switch from blast to cruise with a long-acting undecanoate?: The switch from blast to cruise is typically triggered by reaching a pre-planned accumulation target — often confirmed by a serum testosterone measurement showing stable supraphysiological levels — combined with a structured assessment of recovery markers such as haematocrit, blood pressure, and lipid panels. With Testosterone Undecanoate, practitioners reduce the injected volume rather than changing compounds, maintaining protocol continuity.
How is the 250mg/ml concentration useful when adjusting volume between cruise and blast phases?: At 250mg/ml, each 0.5ml increment represents a meaningful and measurable dose adjustment, giving the practitioner fine-grained control when stepping down from blast-phase volumes to cruise-phase volumes using the same vial. This avoids the need to switch between product concentrations mid-cycle, reducing calculation errors. HPLC verification of the stated concentration means dose calculations are built on confirmed API content rather than label assumption.
What are the storage requirements for a Nassa Labs Testosterone Undecanoate 10ml vial once opened?: Once a multi-dose vial is broached, it should be stored upright at controlled room temperature (15–25°C), away from direct light and heat, and used within the period specified on the product label — typically 28 days after first puncture. Refrigeration is not required but the vial must never be frozen, as this can alter the oil carrier. Each draw should be taken with a fresh, sterile needle to prevent contamination across the long multi-dose cycle. (2) angle_used

Manufacturer

Pricing accessibility is a defined pillar of Nassa Labs' market positioning — the company structures its Testosterone Undecanoate 250mg/ml 10ml vial price point so that athletes running extended cruise-and-blast programmes can sustain multi-phase cycling without the cost burden that has historically made long-acting undecanoate protocols the preserve of those with premium pharmaceutical access. This pricing philosophy is not achieved by reducing analytical oversight: batch release remains conditional on passing HPLC content assay and LAL endotoxin screening before any lot is allocated a distribution code. What Nassa Labs argues, and what its lot-traceability system supports, is that affordable and analytically verified are not mutually exclusive — the cost structure is designed around manufacturing efficiency and direct-to-market distribution rather than reduced testing scope. For practitioners who require consistent, documented-quality testosterone across a protocol spanning several months, the per-vial price of Nassa Labs Testosterone Undecanoate represents the compound's full analytical certification cost distributed across a multi-dose 10ml supply.

Product details

Brand	Nassa Labs
Active ingredient	testosterone undecanoate injection
Also known as	Testosterone Undecanoat, Nebido, Aveed, Testosteronee Undecanoate, Nassa Labs Testosterone Undecanoat
Strength	250 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TUND-NAS-250-004

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Nebido 1000mg/ml 1x4ml Ampoules by Schering

Established Brand

Nebido 1000mg/ml 1x4ml Ampullen by Schering

Nebido is a long-acting injectable testosterone therapy containing Testosterone Undecanoate at 1000 mg in 4 ml of castor-oil vehicle — a formulation whose clinical development spans more than four decades of endocrinology research and regulatory refinement. Conceived as a depot solution for male hypogonadism requiring infrequent dosing intervals, Nebido emerged from Bayer's pharmaceutical pipeline in the early 2000s after years of pharmacokinetic trials that distinguished it from earlier ester-based testosterone preparations. Quality assurance follows validated in-house protocols: each batch is released only after HPLC-confirmed content uniformity and LAL endotoxin clearance meet the EMA-approved specification thresholds.

€110.00

Long-Acting Formula

Undecanoate 250mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Testosterone Undecanoate Injection is an oil-based androgen depot formulated at 250 mg/ml, distinguished by an exceptionally prolonged pharmacokinetic release curve that maintains supraphysiological testosterone levels for weeks from a single intramuscular injection. The undecanoate ester's 11-carbon fatty-acid chain slows enzymatic cleavage to free testosterone, producing a mean plasma half-life measured between 20 and 34 days in published pharmacokinetic studies. Quality assurance covers each 10 ml vial: HPLC quantification against a certified testosterone reference standard and LAL endotoxin testing are applied at batch level before any unit is released under GMP-compliant production conditions.

€48.00

High Concentration

Testosterone Undecanoate 250mg/ml 10ml Vial by Hilma Biocare

Hilma Biocare Testosterone Undecanoate Injection 250mg/ml is a high-concentration, oil-based injectable depot formulated for extended-interval cycle structures where hormonal stability and infrequent administration are the primary design objectives. The 10ml multi-dose vial provides sufficient volume to span a complete blast or cruise segment, offering athletes who plan their anabolic exposure around minimised injection frequency a logistically coherent supply unit. Every batch meets documented release criteria: HPLC potency verification of the incoming API, GMP-compliant fill-and-finish processing, and LAL endotoxin testing on the sealed finished vial.

€45.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00